Isis Pharmaceuticals to License Anti-Clotting Drug to Bayer
May 04 2015 - 6:48PM
Dow Jones News
By Chelsey Dulaney
Isis Pharmaceuticals Inc. (ISIS) has agreed to license its
experimental anticlotting drug to a Bayer AG (BAYRY, BAYN.XE) unit
for an initial payment of $100 million.
Bayer HealthCare will develop and commercialize the drug. Bayer
plans to evaluate the drug, ISIS-FXI, in patients who can't use
anticoagulants, such as patients with a high risk of bleeding.
Bayer said the drug complements its pipeline of thrombosis
treatments. Thrombosis is a process involving blood-clot formation
that can result in heart attacks and strokes.
Isis Pharmaceuticals is also eligible for a $55 million payment
after a phase-two study in patients with compromised kidney
function. The company will also be eligible for milestone payments
and royalties.
Write to Chelsey Dulaney at chelsey.dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ionis Pharmaceuticals (NASDAQ:IONS)
Historical Stock Chart
From Apr 2023 to Apr 2024